Jazz Pharmaceuticals JAZZ agreed to buy GW Pharmaceuticals GWPH for $7.2 billion last wednesday sending shares of fellow epilepsy-focused biotech companies ZYNE flying.
"The acquisition allows Jazz to become a significant epilepsy player by adding Epidiolex, which exited 2020 with sales annualizing at about $576 million despite a challenging Covid environment and ahead of significant growth driven by a tuberous sclerosis label expansion and broad European launch,"